← Scroll for more →
ELI LILLY & Co (LLY)
Pharmaceutical Preparations
Latest Price
$1373.70
TTM P/E
44.59
Normalized P/E
94.53
TTM Div Yield
0.49%
Fwd Div Yield
0.49%
Book Value
42.78
P/B Ratio
32.11
Valuation metrics
adjust assumptions →EPS: $22.95
Book value / share: $28.13
Formula: √(22.5 × EPS × BVPS)
Graham Number
$120.52
91% downside
Norm. op. income: $7.1B (median of 7yr)
Tax rate: 14%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$27.63
98% downside
Base FCF: $5.2B (median of recent 5yr)
Growth: 21%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$265.10
81% downside
EPS: $22.95
Target P/E: 95×
Formula: EPS × P/E
P/E Fair Value
$2,180.25
+59% upside
Institutional Ownership
90.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Lilly Endowment Inc | 90.38M | $108.40B | 10.13% | -1.52M | 2026-06-30 |
| BlackRock, Inc. | 67.54M | $81.01B | 7.57% | +1.05M | 2026-06-30 |
| Vanguard Capital Management LLC | 53.53M | $64.20B | 6.00% | +167.1K | 2026-06-30 |
| PNC Financial Services Group, Inc. | 51.32M | $61.56B | 5.75% | -6.2K | 2026-06-30 |
| State Street Corp | 36.22M | $43.44B | 4.06% | +605.8K | 2026-06-30 |
| FMR LLC | 28.46M | $34.14B | 3.19% | +2.12M | 2026-06-30 |
| Capital Research Global Investors | 20.87M | $25.04B | 2.34% | -3.76M | 2026-06-30 |
| Vanguard Portfolio Management LLC | 20.86M | $25.02B | 2.34% | -117.8K | 2026-06-30 |
| Geode Capital Management, LLC | 20.31M | $24.27B | 2.28% | +119.0K | 2026-06-30 |
| Morgan Stanley | 16.23M | $19.46B | 1.82% | +788.9K | 2026-06-30 |